Endocrine Abstracts

Background: Systemic adiponectin is reduced in patients with obesity and type 2 diabetes mellitus. Peripheral monocytes of type 2 diabetic patients are activated and show a higher surface abundance of CCR2. Inflammatory markers like CCL2 are elevated in the serum of these patients. Therefore, the influence of adiponectin on the release of CC chemokines and the abundance of the corresponding receptors were investigated in monocytic cells.Methods: Primary ...

Background: Adiponectin was suggested to exert hepatoprotective effects in animal models of tetrachlorcarbonate-, endotoxin- and alcohol-induced liver injury. Further, in patients with non-alcoholic fatty liver disease (NAFLD) low adiponectin levels were found to be associated with more severe steatosis and hepatic inflammation.Methods: To investigate the molecular basis of the hepatoprotective effects of adiponectin primary human hepatocytes were incuba...